{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:59:07Z","timestamp":1768705147071,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1124\/jpet.124.002193","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T15:35:22Z","timestamp":1726500922000},"page":"335-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nonclinical Profile of PF-06952229 (MDV6058), a Novel TGF\u03b2RI\/Activin Like Kinase 5 Inhibitor Supports Clinical Evaluation in Cancer"],"prefix":"10.1016","volume":"391","author":[{"given":"Mausumee","family":"Guha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Son","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Bernales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Vitsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.124.002193_bib1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGFbeta signalling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.124.002193_bib2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","article-title":"Induction of heart valve lesions by small-molecule ALK5 inhibitors","volume":"39","author":"Anderton","year":"2011","journal-title":"Toxicol Pathol"},{"key":"10.1124\/jpet.124.002193_bib3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrc1926","article-title":"Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer","volume":"6","author":"Bierie","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.124.002193_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0092-8674(87)90192-9","article-title":"The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors","volume":"48","author":"Cheifetz","year":"1987","journal-title":"Cell"},{"key":"10.1124\/jpet.124.002193_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","article-title":"Targeting TGF-beta signaling in cancer","volume":"3","author":"Colak","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1124\/jpet.124.002193_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1358\/dnp.2006.19.2.977444","article-title":"Inhibition of ALK5 as a new approach to treat liver fibrotic diseases","volume":"19","author":"de Gouville","year":"2006","journal-title":"Drug News Perspect"},{"key":"10.1124\/jpet.124.002193_bib7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0192623310378027","article-title":"Drug-induced valvulopathy: an update","volume":"38","author":"Elangbam","year":"2010","journal-title":"Toxicol Pathol"},{"key":"10.1124\/jpet.124.002193_bib8","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/liv.14113","article-title":"Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma","volume":"39","author":"Faivre","year":"2019","journal-title":"Liver Int"},{"key":"10.1124\/jpet.124.002193_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222259","article-title":"Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-betaRI inhibitor galunisertib","volume":"15","author":"Giannelli","year":"2020","journal-title":"PLoS One"},{"key":"10.1124\/jpet.124.002193_bib10","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bcp.12256","article-title":"Defining a therapeutic window for the novel TGF-beta inhibitor LY2157299 monohydrate based on a pharmacokinetic\/pharmacodynamic model","volume":"77","author":"Gueorguieva","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.124.002193_bib11","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/jpet.124.002193_bib12","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/jm500115w","volume":"57","author":"Jin","year":"2014","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.124.002193_bib13","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s10637-019-00835-y","article-title":"Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study","volume":"38","author":"Jung","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1124\/jpet.124.002193_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","article-title":"Novel therapies emerging in oncology to target the TGF-beta pathway","volume":"14","author":"Kim","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1124\/jpet.124.002193_bib15","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1021\/jm701199p","article-title":"Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent","volume":"51","author":"Li","year":"2008","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.124.002193_bib16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI69942","article-title":"Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis","volume":"124","author":"Li","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.124.002193_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-00436-9","article-title":"Targeting TGFbeta signal transduction for cancer therapy","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1124\/jpet.124.002193_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","article-title":"TGFbeta in cancer","volume":"134","author":"Massagu\u00e9","year":"2008","journal-title":"Cell"},{"key":"10.1124\/jpet.124.002193_bib19","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3892\/ijo.2015.2816","article-title":"Role of TGFbeta in regulation of the tumor microenvironment and drug delivery (review)","volume":"46","author":"Papageorgis","year":"2015","journal-title":"Int J Oncol"},{"key":"10.1124\/jpet.124.002193_bib20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/labinvest.3700669","article-title":"Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations","volume":"87","author":"Prud'homme","year":"2007","journal-title":"Lab Invest"},{"key":"10.1124\/jpet.124.002193_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128979","article-title":"Discovery of MDV6058 (PF-06952229), a selective and potent TGF\u03b2R1 inhibitor: design, synthesis and optimization","volume":"75","author":"Pujala","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.124.002193_bib22","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jat.3954","article-title":"Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS-986260, mitigates class-based cardiovascular toxicity in dogs but not rats","volume":"40","author":"Rak","year":"2020","journal-title":"J Appl Toxicol"},{"key":"10.1124\/jpet.124.002193_bib23","first-page":"1","article-title":"Nonclinical safety evaluation of a transforming growth factor \u03b2 receptor I kinase inhibitor in Fischer 344 rats and beagle dogs","volume":"4","author":"Stauber","year":"2014","journal-title":"J Clin Toxicol"},{"key":"10.1124\/jpet.124.002193_bib24","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/0008-5472.CAN-06-2389","article-title":"A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection","volume":"67","author":"Suzuki","year":"2007","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.124.002193_bib25","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1158\/0008-5472.CAN-04-1013","article-title":"SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo","volume":"64","author":"Uhl","year":"2004","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.124.002193_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1021\/acsmedchemlett.9b00552","article-title":"Discovery of BMS-986260, a potent, selective, and orally bioavailable TGFbetaR1 inhibitor as an immuno-oncology agent","volume":"11","author":"Velaparthi","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/jpet.124.002193_bib27","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.18632\/oncotarget.23795","article-title":"Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-beta receptor type I inhibitor","volume":"9","author":"Yingling","year":"2018","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.124.002193_bib28","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1158\/1078-0432.CCR-21-1504","article-title":"First-in-human phase I study of a next-generation, oral, TGFbeta receptor 1 inhibitor, LY3200882, in patients with advanced cancer","volume":"27","author":"Yap","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524178093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524178093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.124.002193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T14:12:13Z","timestamp":1743257533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524178093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0022356524178093"],"URL":"https:\/\/doi.org\/10.1124\/jpet.124.002193","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonclinical Profile of PF-06952229 (MDV6058), a Novel TGF\u03b2RI\/Activin Like Kinase 5 Inhibitor Supports Clinical Evaluation in Cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.124.002193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}